Vivos Therapeutics (VVOS) Revenue (2020 - 2026)

Vivos Therapeutics (VVOS) has 7 years of Revenue data on file, last reported at $5.1 million in Q1 2026.

• On a quarterly basis, Revenue rose 70.46% year-over-year to $5.1 million in Q1 2026; TTM through Mar 2026 was $19.6 million, a 33.77% increase from a year earlier, with the FY2025 full-year figure at $17.4 million, up 16.05% from the prior year.
• Revenue for Q1 2026 stood at $5.1 million, up from $3.8 million in the prior quarter.
• Over the last five years, Revenue for VVOS reached as high as $6.8 million in Q3 2025 and fell as low as $3.0 million in Q1 2025.
• Historically, Revenue has averaged $4.0 million across 5 years, with a median of $3.8 million in 2025.
• Across the five-year window, Revenue decreased 22.26% in 2023 and soared 75.73% in 2025, its largest moves.
• Year by year, Revenue stood at $4.0 million in 2022, then slipped by 17.77% to $3.2 million in 2023, then advanced by 13.85% to $3.7 million in 2024, then grew by 3.41% to $3.8 million in 2025, then soared by 34.44% to $5.1 million in 2026.
• Per Business Quant data, the three most recent Revenue figures were $5.1 million in Q1 2026, $3.8 million in Q4 2025, and $6.8 million in Q3 2025.